Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTP-01
- Development stage
- Phase 1
- Lead developer
- University of Virginia Foundation
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
PTP-01 is a peptide conjugate radionuclide developed as a diagnostic radiopharmaceutical for use with SPECT (Single-photon emission computed tomography) imaging. It was initially developed by the University of Virginia Foundation to enhance the detection of pancreatic cancer, specifically pancreatic ductal adenocarcinoma, by targeting plectin—a biomarker highly specific to pancreatic cancer cells. The drug was designed to improve sensitivity in detecting small or early-stage pancreatic cancers that are often missed by conventional CT or MRI scans. Its mechanism involves acting as an enhancer for SPECT imaging, allowing better visualization of neoplastic tissue during diagnostic procedures[1].
Beyond the preview
Go deeper on PTP-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTP-01.